Welcome to IsraPharm - Contact us at +972 7337 468 45 (Office)

Contact Us

Office Address

Weizman 14 st., Tel Aviv, Israel

Phone Number

+972 7337 46845 (Office)

Email Address

[email protected]



In Stock

Add to Wishlist
Add to Wishlist


The World Health Organization (WHO) has recommended the drugs nirmatrelvir and ritonavir, sold under the name Paxlovid, for the treatment of COVID-19 patients with mild or non-severe illness but at high risk of hospitalization. WHO called this drug “the best therapeutic tool to date.”
Pfizer’s (2023) oral antiviral is recommended for patients who are most at risk of developing severe illness and hospitalization. This group includes the unvaccinated, the elderly, or people taking immune-suppressing drugs.
The recommendation is based on new data from two randomized controlled trials involving 3078 patients. The results show that the risk of hospitalization after such treatment is reduced by 85 %.

Active Ingredients: nirmatrelvir and ritonavir

Prescription medicine.

Additional information

Действующее вещество

нирматрелвир и ритонавир

Количество таблеток


Температура хранения

До 25 Градусов

Цена за доставку

До 2 Кг 50 Доларов